NumerixS Investment Technologies’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-3,792
Closed -$124K 570
2020
Q2
$124K Sell
3,792
-10,000
-73% -$319K 0.03% 522
2020
Q1
$415K Sell
13,792
-6,990
-34% -$208K 0.21% 100
2019
Q4
$601K Buy
20,782
+14,382
+225% +$398K 0.12% 196
2019
Q3
$165K Sell
6,400
-28,620
-82% -$724K 0.04% 435
2019
Q2
$894K Buy
35,020
+24,180
+223% +$598K 0.26% 82
2019
Q1
$282K Sell
10,840
-9,960
-48% -$245K 0.04% 553
2018
Q4
$477K Sell
20,800
-7,600
-27% -$169K 0.15% 146
2018
Q3
$676K Buy
28,400
+24,400
+610% +$595K 0.13% 229
2018
Q2
$91K Buy
+4,000
New +$95.1K 0.02% 783
2017
Q4
Sell
-26,600
Closed -$640K 1290
2017
Q3
$640K Sell
26,600
-21,200
-44% -$479K 0.14% 174
2017
Q2
$1.02M Buy
+47,800
New +$965K 0.15% 163
2016
Q4
Sell
-136,822
Closed -$2.85M 1277
2016
Q3
$2.85M Buy
+136,822
New +$3.39M 0.37% 49
2015
Q3
Sell
-8,200
Closed -$225K 740
2015
Q2
$225K Buy
+8,200
New +$231K 0.03% 572
2015
Q1
Sell
-19,568
Closed -$414K 655
2014
Q4
$414K Buy
+19,568
New +$437K 0.14% 220

Other funds holding NVO

NumerixS Investment Technologies's NVO Position: Q3 2020 in Review

NumerixS Investment Technologies sold out of Novo Nordisk (NVO) in Q3 2020, closing a stake of 3,792 shares — an estimated $124K sold.

NumerixS Investment Technologies first reported a position in NVO in Q4 2014 and held it in 14 quarters. The position peaked at $2.85M in Q3 2016. 659 funds tracked by Wall St. Rank hold NVO as of Q3 2020.

  • NumerixS Investment Technologies reported no remaining Novo Nordisk position as of Q3 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 3,792 Novo Nordisk shares in Q3 2020, an estimated $124K.
  • NumerixS Investment Technologies first reported a position in Novo Nordisk in Q4 2014 and held it in 14 quarters.
  • NumerixS Investment Technologies's Novo Nordisk position peaked at $2.85M in Q3 2016.
  • 659 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2020.

Based on NumerixS Investment Technologies's 13F filing for Q3 2020.